Dexcom, a notable player in real-time continuous glucose monitoring (rtCGM) globally, confirmed today that Health Canada has given its approval for the next-generation Dexcom G7 Continuous Glucose Monitoring System.

The product is intended for people aged two and above who have any type of diabetes. Dexcom Canada, however, has mentioned that the device is not currently available for purchase. The company aims to have Dexcom G7 available to Canadians living with diabetes by the end of 2023.

Diabetes, which is known to affect more than three million Canadians according to the Public Health Agency of Canada, requires vigilant monitoring of glucose levels and regular decision-making for effective disease management.

The approval of Dexcom G7 by Health Canada introduces a new tool to Canadians, which Dexcom states, simplifies diabetes management and reduces the risk of hospitalizations and emergency room visits resulting from hypoglycemia.

The Dexcom G7 system integrates an all-in-one sensor and transmitter that warms up twice as fast as other CGMs currently available on the market. It enables users to monitor their glucose levels in real-time, delivering automatic readings to a compatible smart device or receiver, without the need for regular finger pricks or scans.

A suite of customizable alerts in the system can warn of high or low glucose levels and predict urgent low alerts to potentially prevent dangerous hypoglycemic events. It also provides remote monitoring and reporting capabilities, allowing users to share information with their care team and loved ones anytime, anywhere.

The new Dexcom G7 boasts a range of features and enhancements. It’s touted as the smallest Dexcom sensor yet, 60% smaller than the Dexcom G6, and offers multiple approved wear locations for comfort and discretion.

With a simplified CGM system and experience, faster sensor warmup, and a 12-hour grace period to replace finished sensors, Dexcom G7 aims to offer convenience and flexibility to users. Other advancements include improved alert customization to meet individual needs and preferences and a redesigned and simplified mobile app with Dexcom Clarity integration.

As a part of its growth strategy, Dexcom is collaborating with insulin pump partners to incorporate the Dexcom G7 into current and future automated insulin delivery systems.

André Côté — Dexcom Canada Vice President and General Manager said: “With our latest advancements in sensor technology and software integrations, we’re entering a new era of diabetes care with continuous glucose monitoring at the centre. Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians.

“With greater accuracy, a simplified user experience, proven results and extensive digital connectivity, our next-generation Dexcom G7 will support greater quality of life and improved outcomes for people with diabetes, and we couldn’t be more excited to bring it to Canada by the end of 2023.”

  André Côté, Canada, Dexcom, Dexcom G7, Diabetes, Diabetes management, Health Canada, medical device industry news